Broncus Unit to Acquire Preferred Shares in Medical Firm; Shares Jump 4%
MT Newswires Live
Dec 30, 2025
Broncus (HKG:2216) unit Broncus China agreed to acquire 157,800 Series B preferred shares in Valgen from Venus Medtech (Hong Kong) for HK$15 million, according to a Monday Hong Kong bourse filing.
Shares of the lung disease treatment firm were up nearly 4% in Tuesday afternoon trading.
Each preferred share will automatically be converted into an ordinary share upon the closing of a qualified IPO.
The shares represent 1.05% of the outstanding shares of the target firm on a fully diluted and as converted basis.
The target firm engages mainly in providing systematic solutions for diseases such as mitral regurgitation and tricuspid regurgitation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.